Interleukin-10 and transforming growth factor-β in early and late lesions of patients with Leishmania major induced cutaneous leishmaniasis

Iranian Journal of Parasitology

Volumn 7, Issue 2, 2012, Pages 53-60

  Hejazi, S H ^a   Hoseini, S G ^b   Javanmard, S H ^c   Zarkesh, S H ^b   Khamesipour, A ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Immunofluorescence; Interleukin 10; Leishmania major; Transforming growth factor

Indexed keywords

INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FROZEN SECTION; HUMAN; IMMUNOFLUORESCENCE TEST; LEISHMANIA MAJOR; MALE; SKIN BIOPSY; SKIN LEISHMANIASIS;

EID: 84862337172     PISSN: 17357020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol. 1996 Sep-Oct;14(5):425-431.
2. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Mi-crobiol Infect Dis. 2004 Sep;27(5):305-318.
3. Dowlati Y. Treatment of cutaneous leishmaniasis (Old World). Clin Dermatol. 1996 Sep-Oct;14(5):513-517.
4. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2:845-858.
5. Belkaid Y, Piccirillo CA, Mendez S, She-vach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002 Dec 5;420(6915):502-507.
6. Xu DLH, Komai-Koma M, Campbell C, McSharry C, Alexander J, Liew FY. CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol. 2003;170:394-399.
7. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
8. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. Oct;21(5):331-344.
9. Gordon S. Alternative activation of macro-phages. Nat Rev Immunol. 2003 Jan;3(1):23-35.
10. Shalev I, Schmelzle M, Robson SC, Levy G. Making sense of regulatory T cell suppressive function. Semin Immunol. 2011 May 16
11. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Pa-lomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun. 1994 Mar;62(3):837-842.
12. Diaz NL, Zerpa O, Ponce LV, Convit J, Rondon AJ, Tapia FJ. Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterization of the lesion. Exp Derma-tol. 2002 Feb;11(1):34-41.
13. Nasereddin A, Jaffe CL. Rapid diagnosis of Old World Leishmaniasis by high-resolution melting analysis of the 7SL RNA gene. J Clin Microbiol. 2010 Jun;48(6):2240-2242.
14. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol. 2001 Jan 15;166(2):1141-1147.
15. Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol. 1999 Feb 1;162(3):1723-1729.
16. Viana da Costa A, Huerre M, Delacre M, Auriault C, Correia Costa JM, Verwaerde C. IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. Parasitol Int. 2002 Dec;51(4):367-379.
17. Belkaid Y. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med. 2001;194:1497-1506.
18. Louzir H, Melby PC, Ben Salah A, Marrak-chi H, Aoun K, Ben Ismail R, et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis. 1998 Jun;177(6):1687-1695.
19. Bourreau E, Prevot G, Gardon J, Pradi-naud R, Launois P. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J Infect Dis. 2001 Dec 15;184(12):1628-1630.
20. Bourreau E, Ronet C, Darcissac E, Lise MC, Sainte Marie D, Clity E, et al. Intrale-sional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun. 2009 Apr;77(4):1465-1474.
21. Gaafar A, Veress B, Permin H, Kharazmi A, Theander TG, El Hassan AM. Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol. 1999 Jun;91(3):314-320.
22. Machado PR, Rosa ME, Costa D, Mignac M, Silva JS, Schriefer A, et al. Reappraisal of the immunopathogenesis of disseminated leishmaniasis: in situ and systemic immune response. Trans R Soc Trop Med Hyg. 2011 Aug;105(8):438-444.
23. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun. 2000 Apr;68(4):1760-1764.
24. Habibi GR, Khamesipour A, McMaster WR, Mahboudi F. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand J Immunol. 2001 Oct;54(4):414-420.
25. Jafari-Shakib R, Ajdary S, Amiri ZM, Mo-hammadi AM, Nourijelyani K, Mortazavi H, et al. CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis. Clin Exp Immunol. 2008 Jul;153(1):31-36.
26. Nilsen R, Mshana RN. In situ characterization of the cutaneous immune response in Ethiopian cutaneous leishmaniasis. Scand J Immunol. 1987 Nov;26(5):503-512.
27. Enk AH, Katz SI. Identification and induction of keratinocyte-derived IL-10. J Immunol. 1992 Jul 1;149(1):92-95.
28. O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007 Jun;7(6):425-428.
29. O'Garra A, Vieira PL, Vieira P, Goldfeld AE. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest. 2004;114:1372-1378.
30. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med. 2007 Feb 19;204(2):285-297.
31. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med. 2006 Mar 20;203(3):777-788.
32. Reed SG. TGF-beta in infections and infectious diseases. Microbes Infect. 1999 Dec;1(15):1313-1325.
33. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003 Jan 15;116(Pt 2):217-224.
34. Ferguson MW, O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2004 May 29;359(1445):839-850.